Subscribe to Drug Discovery & Development for your weekly roundup of the latest strategies & technologies related to biopharma, #biotech, cell & gene therapy, and pharmaceutical R&D: https://t.co/WWng2xmeEW

From monoclonal antibodies to CAR T, oncology biosimilars face scientific, regulatory, and adoption challenges. Learn how sponsors can prepare: https://t.co/ZM9ZU3KB2F

Beyond approvals, uptake of biosimilars depends on education, real-world data, and trusted communication with providers and patients. https://t.co/ZM9ZU3KB2F

Physician buy-in is essential for oncology biosimilar adoption. Misconceptions about quality and trial rigor persist—here’s how to address them: https://t.co/ZM9ZU3KB2F

Subscribe to Drug Discovery & Development for your weekly roundup of the latest strategies & technologies related to biopharma, #biotech, cell & gene therapy, and pharmaceutical R&D: https://t.co/WWng2xmeEW

Single‑use pump innovation: integrated bypass systems bring built-in pressure relief and seamless recirculation—no external components needed. Discover how it's shaping biopharma design: https://t.co/S1i72yJjDi

As biosimilars for cell therapies like CAR T emerge, questions remain: can regulatory bodies accept similarity in inherently unique therapies? https://t.co/ZM9ZU3KB2F

Add pressure resilience to your biopharma workflows. Integrated bypass in single‑use pumps ensures automatic recirculation and avoids process interruptions. Read more: https://t.co/S1i72yJjDi

Recruiting patients for oncology biosimilar trials is harder than it seems—especially when the originator drug is already approved and accessible. https://t.co/ZM9ZU3KB2F

The 2025 Pharma 50 Deep Dives report goes beyond the rankings, identifying high-momentum drugs, tracking major decliners, analyzing biosimilar-driven market erosion, and examining the regulatory pressures shaping 2025. Access the free report: https://t.co/ZmboWKgVoj

Looking to bypass pressure-related failures? Next-gen single-use pumps integrate bypass circuits that trigger under overpressure—boosting safety and uptime. Learn more: https://t.co/S1i72yJjDi

Elevate your single‑use pump design: integrated bypass provides automatic flow recirculation during back‑pressure events—improving lifespan and system resilience. Details here: https://t.co/S1i72yJjDi

Monoclonal antibody biosimilars are growing—but ensuring consistent quality remains difficult due to manufacturing sensitivity and variability. https://t.co/ZM9ZU3KB2F

Biopharmaceutical systems demand both simplicity and safety. Integrated bypass in single‑use pumps delivers both—protecting systems while keeping setup lean. Read how: https://t.co/S1i72yJjDi

Patent expirations open doors for oncology biosimilars, but complex modalities like ADCs, BsAbs, and CAR T cell therapies raise the bar. Explore why: https://t.co/ZM9ZU3KB2F

Single‑use pumps now offer adjustable bypass systems that preserve flow control and reduce back-pressure—without external valves or complex piping. Explore the benefits: https://t.co/S1i72yJjDi

When pressure spikes arise, integrated bypass technology acts fast—recirculating flow automatically, protecting costly process systems. Discover how: https://t.co/S1i72yJjDi

Oncology biosimilars can dramatically lower cancer treatment costs—but developing them is far from simple. Learn what makes them uniquely challenging: https://t.co/ZM9ZU3KB2F

Geared toward biopharma production? Integrated bypass tech in single‑use pump design offers dynamic pressure control and recirculation—boosting pump safety and performance. Learn more: https://t.co/S1i72yJjDi

The 2025 Pharma 50 Deep Dives report reveals how key shifts in #pharma have reshaped the industry: 💊 Mounjaro surged 124% 💊 Oncology leads with $84B in sales 💊 Biosimilars are disrupting established blockbusters Download your free copy today: https://t.co/ZmboWKgVoj